🚀 VC round data is live in beta, check it out!
Aurinia Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aurinia Pharmaceuticals and similar public comparables like Cheezheng Tibetan Medicine, Harrow, Phibro Animal Health, Eris Lifesciences and more.
Aurinia Pharmaceuticals Overview
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Founded
2011
HQ
Employees
128
Website
Sectors
Financials (LTM)
EV
$2B
Aurinia Pharmaceuticals Financials
Aurinia Pharmaceuticals reported last 12-month revenue of $292M and EBITDA of $160M.
In the same LTM period, Aurinia Pharmaceuticals generated $259M in gross profit, $160M in EBITDA, and $249M in net income.
Revenue (LTM)
Aurinia Pharmaceuticals P&L
In the most recent fiscal year, Aurinia Pharmaceuticals reported revenue of $283M and EBITDA of $150M.
Aurinia Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $292M | XXX | $283M | XXX | XXX | XXX |
| Gross Profit | $259M | XXX | $250M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 89% | XXX | XXX | XXX |
| EBITDA | $160M | XXX | $150M | XXX | XXX | XXX |
| EBITDA Margin | 55% | XXX | 53% | XXX | XXX | XXX |
| EBIT Margin | 37% | XXX | 38% | XXX | XXX | XXX |
| Net Profit | $249M | XXX | $287M | XXX | XXX | XXX |
| Net Margin | 85% | XXX | 102% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aurinia Pharmaceuticals Stock Performance
Aurinia Pharmaceuticals has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Aurinia Pharmaceuticals' stock price is $15.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $2.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAurinia Pharmaceuticals Valuation Multiples
Aurinia Pharmaceuticals trades at 5.7x EV/Revenue multiple, and 10.5x EV/EBITDA.
EV / Revenue (LTM)
Aurinia Pharmaceuticals Financial Valuation Multiples
As of March 21, 2026, Aurinia Pharmaceuticals has market cap of $2B and EV of $2B.
Equity research analysts estimate Aurinia Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aurinia Pharmaceuticals has a P/E ratio of 8.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | 10.5x | XXX | 11.2x | XXX | XXX | XXX |
| EV/EBIT | 15.3x | XXX | 15.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.5x | XXX | 6.7x | XXX | XXX | XXX |
| P/E | 8.0x | XXX | 7.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 12.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aurinia Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aurinia Pharmaceuticals Margins & Growth Rates
Aurinia Pharmaceuticals' revenue in the last 12 month grew by 16%.
Aurinia Pharmaceuticals' revenue per employee in the last FY averaged $2.3M.
Aurinia Pharmaceuticals' rule of 40 is 70% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aurinia Pharmaceuticals' rule of X is 94% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Aurinia Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 55% | XXX | 53% | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | 29% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 70% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 94% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 35% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aurinia Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cheezheng Tibetan Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Harrow | XXX | XXX | XXX | XXX | XXX | XXX |
| Phibro Animal Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Eris Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Nektar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aurinia Pharmaceuticals M&A Activity
Aurinia Pharmaceuticals acquired XXX companies to date.
Last acquisition by Aurinia Pharmaceuticals was on XXXXXXXX, XXXXX. Aurinia Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aurinia Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAurinia Pharmaceuticals Investment Activity
Aurinia Pharmaceuticals invested in XXX companies to date.
Aurinia Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Aurinia Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aurinia Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aurinia Pharmaceuticals
| When was Aurinia Pharmaceuticals founded? | Aurinia Pharmaceuticals was founded in 2011. |
| Where is Aurinia Pharmaceuticals headquartered? | Aurinia Pharmaceuticals is headquartered in United States. |
| How many employees does Aurinia Pharmaceuticals have? | As of today, Aurinia Pharmaceuticals has over 128 employees. |
| Who is the CEO of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals' CEO is Peter S. Greenleaf. |
| Is Aurinia Pharmaceuticals publicly listed? | Yes, Aurinia Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals trades under AUPH ticker. |
| When did Aurinia Pharmaceuticals go public? | Aurinia Pharmaceuticals went public in 2009. |
| Who are competitors of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals main competitors are Cheezheng Tibetan Medicine, Harrow, Phibro Animal Health, Eris Lifesciences. |
| What is the current market cap of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals' current market cap is $2B. |
| What is the current revenue of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals' last 12 months revenue is $292M. |
| What is the current revenue growth of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Aurinia Pharmaceuticals? | Current revenue multiple of Aurinia Pharmaceuticals is 5.7x. |
| Is Aurinia Pharmaceuticals profitable? | Yes, Aurinia Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals' last 12 months EBITDA is $160M. |
| What is Aurinia Pharmaceuticals' EBITDA margin? | Aurinia Pharmaceuticals' last 12 months EBITDA margin is 55%. |
| What is the current EV/EBITDA multiple of Aurinia Pharmaceuticals? | Current EBITDA multiple of Aurinia Pharmaceuticals is 10.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.